De Toni EN, et al. - Using data from the Munich Cancer Registry, researchers ascertained if the enactment of screening policies and the better treatment options made for better real-world survival in patients with hepatocellular carcinoma (HCC). There were 4,078 patients diagnosed with HCC between 1998 and 2016, who were assessed. From 1998-2002 to 2008–2016, median overall survival increased from 6 months to 12 months. According to the results from this multicenter study in Southern Germany, the incidence of HCC over the last 18 years remained unchanged, contrary to current assumptions. Likely due to screening program implementation, earlier diagnosis allowed for increasing use of effective therapeutic options and a survival benefit in those without diagnostic metastases, regardless of age. This is the first study showing that the advances in HCC prevention and treatment, well documented in clinical studies, translated into a general population survival advantage for HCC patients.